Literature DB >> 19584854

Antibody affinity maturation and respiratory syncytial virus disease.

Christine A Shaw, Gillis Otten, Andreas Wack, Gene A Palmer, Christian W Mandl, M Lamine Mbow, Nicholas Valiante, Philip R Dormitzer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19584854     DOI： 10.1038/nm0709-725a

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  2 in total

1.  The TLR4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus vaccine-enhanced disease.

Authors:  Marina S Boukhvalova; Gregory A Prince; Layla Soroush; Dolores C Harrigan; Stefanie N Vogel; Jorge C G Blanco
Journal:  Vaccine       Date:  2006-04-18       Impact factor: 3.641

2.  Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease.

Authors:  Maria Florencia Delgado; Silvina Coviello; A Clara Monsalvo; Guillermina A Melendi; Johanna Zea Hernandez; Juan P Batalle; Leandro Diaz; Alfonsina Trento; Herng-Yu Chang; Wayne Mitzner; Jeffrey Ravetch; José A Melero; Pablo M Irusta; Fernando P Polack
Journal:  Nat Med       Date:  2008-12-14       Impact factor: 53.440
  2 in total
  4 in total

Review 1.  New insights for development of a safe and protective RSV vaccine.

Authors:  Jorge C G Blanco; Marina S Boukhvalova; Kari Ann Shirey; Gregory A Prince; Stefanie N Vogel
Journal:  Hum Vaccin       Date:  2010-06-01

Review 2.  Respiratory syncytial virus vaccine development.

Authors:  Julia L Hurwitz
Journal:  Expert Rev Vaccines       Date:  2011-10       Impact factor: 5.217

Review 3.  Respiratory syncytial virus: current progress in vaccine development.

Authors:  Rajeev Rudraraju; Bart G Jones; Robert Sealy; Sherri L Surman; Julia L Hurwitz
Journal:  Viruses       Date:  2013-02-05       Impact factor: 5.048

Review 4.  Priorities for developing respiratory syncytial virus vaccines in different target populations.

Authors:  Simon B Drysdale; Rachael S Barr; Christine S Rollier; Christopher A Green; Andrew J Pollard; Charles J Sande
Journal:  Sci Transl Med       Date:  2020-03-18       Impact factor: 19.319
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.